Journal
PHYTOMEDICINE
Volume 92, Issue -, Pages -Publisher
ELSEVIER GMBH
DOI: 10.1016/j.phymed.2021.153740
Keywords
Vasculogenic mimicry; Proliferation; Apoptosis; Daurisoline; Sorafenib
Categories
Funding
- Interdisciplinary Program of Shanghai Jiao Tong University [YG2017MS29]
- National Natural Science Foundation of China (NSFC) [81602524, 81572449]
- Songjiang Science and Technology Project [19SJKJGG33]
- Potential Discipline of Shanghai Jiao Tong University School of Medicine [0509N16001]
- National Key R&D Program of China [2017YFC090990]
Ask authors/readers for more resources
This study identified daurisoline (DS) as a potential anticancer agent for hepatocellular carcinoma (HCC) by inhibiting cell proliferation, inducing apoptosis, and repressing vasculogenic mimicry (VM) formation. DS was found to sensitize HCC cells to sorafenib and inhibit VM through inactivation of RhoA/ROCK2-mediated AKT and ERK-p38 MAPK signaling pathways.
Background: Vasculogenic mimicry (VM) is a newly described tumor vascular phenomenon that is independent of traditional angiogenesis and provides an adequate blood supply for tumor growth. VM has been consistently observed in different cancer types. Hence, inhibition of VM may be considered a new anticancer therapeutic strategy. Purpose: This study aimed to elucidate the potential anticancer effect of daurisoline (DS) on hepatocellular carcinoma (HCC) and the potential molecular mechanism by which DS inhibits VM. We also verified whether combination treatment with sorafenib and DS constitutes a novel therapeutic approach to prevent HCC progression. Methods: The effects of DS on proliferation were evaluated by Cell Counting Kit-8 (CCK-8), colony formation, and 5-ethynyl-2'-deoxyuridine (EdU) incorporation assays. 4',6-Diamidino-2-phenylindole (DAPI) staining and flow cytometric analysis were employed to investigate its effects on apoptosis. Western blot analysis, Matrigel tube formation assays, pulldown assays and immunofluorescence staining were applied to validate the potential mechanism by which DS inhibits VM. Mouse xenograft models were used to evaluate anticancer activities. Results: DS inhibited HCC cell proliferation, induced HCC cell apoptosis and repressed VM formation by inactivating RhoA/ROCK2-mediated AKT and ERK-p38 MAPK signaling. Additionally, DS dramatically sensitized HCC cell lines to sorafenib, a curative anticancer drug for patients with advanced HCC. Conclusions: Our study provides insights into the molecular mechanisms underlying DS-induced inhibition of VM, which may facilitate the development of a novel clinical anti-HCC drug. Moreover, our findings suggest that the combination of DS and sorafenib constitutes a potential therapeutic strategy for HCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available